NCT01124656View on ClinicalTrials.gov

Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes

PHASE3TerminatedINTERVENTIONAL

Enrollment

26

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Pioglitazone-Azilsartan

Pioglitazone-Azilsartan (30 mg + 20 mg) or (45 mg + 20 mg), tablets, orally, once daily for up to 52 weeks.

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Takeda

INDUSTRY